Endocrine Abstracts

IntroductionDiabetes, a metabolic disorder characterized by abnormal blood glucose levels, is a serious chronic disease that implies an important public health problem. Being Insulin the main hormone for modulating blood glucose levels, subcutaneous injections are the main way for its administration in the diabetes treatment. However, this way of administration can lead to poor patient compliance, apart from several side-effects. Although other ways of a...

Introduction: The purpose of this study was to describe the clinical characteristics of patients with macroprolactinoma in a second level Hospital.Methods: Retrospective data collection of patients diagnosed with macroprolactinoma between 2002 and 2017 at Jerez University Hospital.Results: Complete Data were obtained from 22 patients. The mean age at diagnosis was 40.32 ± 18.3 years (men: 52.9 ± 14.2, women: 27.7 ± 1...

Introduction: Papillary carcinoma is the most common form of well-differentiated thyroid cancer (80% of the total). In recent years there has been a significant progressive increase in prevalence.Objectives: The aim of the study was to evaluate the clinical characteristics of the newly diagnosed papillary thyroid carcinoma at the Sanitary Area of Jerez, as well as to analyze its incidence in recent years.Material and Methods: An ob...

Introduction: Once-daily liraglutide and once-weekly dulaglutide, both glucagón-like peptide-1 receptor agonists, improve glycemic control and reduce weight in patients with type 2 diabetes mellitus (T2DM) with a similar efficacy according to head-to-head trial AWARD-6. Nevertheless, there is a lack of evidence in a real-world setting. The focus of our study is to assess changes in glycemic control and weight resulting from switching from liraglutide to dulaglutide in pat...

Introduction: Glucagon-like peptide-1 agonists (GLP1a) and dipeptidyl peptidase-4 inhibitors (DPP4i) are both incretin-based therapies for type 2 diabetes (T2DM) but with distinct efficacy according to glycemic and weight control and side effect profiles. There is scarce information about changes observed after switching from a DPP4i to a GLP1a in patients with T2DM on a complex treatment regimen and routine clinical practice conditions. To assess these changes, we carried out...

Objectives: To assess whether the degree of heterogeneity of thyroid nodules defined by their elastographic characteristics is related to the cytological diagnosis and ultrasound classification of risk of malignancy.Material and Methods: Observational, prospective study. 101 thyroid nodules were analysed by quantitative elastographic analysis (shear-wave), measuring the stiffness of the lesion by global elastography and its standard deviation (s.d.</...

Introduction: The analysis of the signaling pathways involved in vascular calcification is difficult due largely to the limitation in obtaining vascular tissue samples. Therefore, the use of bioinformatics tools for the identification of potential biomarkers associated with vascular calcification is an advantage for the advancement in the knowledge of the molecular pathways involved in this pathology.Objective: Increase understanding of the molecular mec...

Introduction: One of the often-discussed topics in the management guidelines for Type 1 Diabetes Mellitus (T1DM) is the ideal time gap that should exist between patient check-ups. A period of three to six months is usually recommended, which sometimes is difficult to achieve due to the high number of patients. But to what extent does the time gap between appointments in the follow-up of T1DM patients affect their diabetes’ control?Objectives: To kn...

Objectives: We studied whether the postoperative serum thyroglobulin (TG) basal levels before treatment with I131 (baseline TG) could be related with the response to treatment. We consider the excellent response as the absence of clinical, biochemical disease (undetectable TG and anti-thyroglobulin antibodies AcTG negative) and/or structural disease.Material and Methods: This is an observational study that includes 100 patients with differentiated thyroi...

Background and aims: Bexarotene is the first retinoid receptor X (RXR)-selective agonist approved for cutaneous T-cell lymphoma in patients resistant to at least one previus systemic treatment. However, it produces often two endocrine-metabolic alterations: central hypothyroidism and dyslipidemia. We assessed, in a group of patients with Mycosis Fungoide or Sezary syndrome treated with bexarotene, the endocrine-metabolic side effects.Patients and methods...